Pfizer (PFE) Wheel Strategy Research
By The Pie , independent options and small-cap research
Published
The Pie is the Nickelpie research desk, not a licensed financial adviser. Nickelpie publishes educational analysis, not personalized investment advice.
| Price | $24.54 | Today | -$0.47 (-1.88%) |
| 52-week range | $23.11 - $28.75 | Position in range | 25% |
| 100 shares cost | $2,454 | Dividend yield | 6.93% |
Where Pfizer trades right now
As of July 24, 2026, Pfizer (PFE) trades at $24.54, down about 2% on the day, in the lower-middle of a tight one-year range of $23.11 to $28.75. It yields roughly 6.9%. At this price, 100 shares cost about $2,500. The combination of a narrow range, deep liquidity, and a big dividend is exactly the calm, boring profile the wheel prefers, with one asterisk worth taking seriously.
What that big yield is telling you
A ~6.9% dividend on a large-cap pharma stock is unusually high, and unusually high yields are rarely generosity, they're the market pricing in doubt. In Pfizer's case the doubts are concrete: patent expirations on key drugs and the steep normalization of COVID-era revenue that once inflated earnings. This is the same lesson the wheel teaches about premium: the fatter the payout, the more carefully you should ask what risk you're being paid to accept.
Support levels worth watching
Reference levels from the one-year range and round numbers, confirm on a chart:
- ~$24, a round number just below the current price and the nearest area to watch.
- ~$23, round-number support sitting right at the 52-week low.
- $23.11, the 52-week low itself; a decisive break below would be a real signal.
A cash-secured put a wheel seller might study
The framework is a cash-secured put near 0.25-0.30 delta, 21-45 days out, at a strike you'd be content owning at. Rather than nominate a round number, we read it off the chain: the panel above names the contract that fits, with its collateral and the premium at the bid. The range here is tight, with the 52-week low at $23.11 only a little under the market, so there is less discount on offer than on a more volatile name.
If assigned, you'd own a high-yielding defensive name near its lows, collect the dividend while you hold, and sell covered calls above your basis, a textbook wheel setup, provided you've made peace with the dividend risk. Model any strike and premium with the wheel calculator, and confirm live numbers on your chain.
The honest risk picture
The core risks are the patent cliff and pipeline dependence: pharma earnings can step down sharply as blockbuster drugs lose exclusivity, and the replacements aren't guaranteed. Add post-pandemic revenue normalization, drug-pricing and regulatory pressure, and the dividend question above. The tight trading range makes Pfizer feel safe, and it is calmer than most, but "calm" and "no risk" aren't the same thing. Wheel it only if you'd be genuinely content holding it through a down leg.
The put the chain supports, PFE
Closest to 0.25 delta between 21 and 45 days, with at least 10 contracts of open interest. Source: CBOE delayed quotes, 2026-07-25 03:44:42. Delayed data, and it will have moved.
The contract
$23.50 put
Aug 28, 2026, 35 days out, 0.25 delta
You are paid
$26
$0.26 bid × 100, against $2,350 of collateral
Yield
1.1%
over 35 days, 12% if repeated all year
Selling this put obligates you to buy 100 shares at $23.50 if PFE is below that on Aug 28, 2026. That strike is 4.2% below the $24.54 close, and because you keep the premium either way your effective cost if assigned is $23.24. Open interest on the contract is 123, and implied volatility is 24%.
How to read this. This is the contract nearest our published convention that also clears a liquidity floor. It is not the highest premium on the board. The fattest premium always sits on the strike most likely to be assigned, which is the opposite of what this entry is for. The annualised figure assumes the same trade repeats every cycle at the same price, which it will not, so treat it as a way to compare two expiries rather than a return you should expect. Quotes are delayed and the chain moves constantly: verify on your broker's live chain before acting. This is educational research, not advice, and not a recommendation to sell this or any option.
Insider activity, PFE
SEC Form 4 filings since Jul 25, 2025. Source: SEC EDGAR, pulled Jul 25, 2026.
Open-market buys
$0.00
0 transactions
Open-market sales
$51.4K
1 transaction, 1 insider
Net open-market activity: -$51.4K. A further 104 filings were stock grants, option exercises or shares withheld to pay vesting tax. Those are not purchases or sales, so they are excluded from the totals above.
| Date | Insider | Action | Shares | Price |
|---|---|---|---|---|
| Jun 9, 2026 | DAMICO JENNIFER B.SVP & Controller | Sold | 2,000 | $25.70 |
How to read this. A purchase is the only line here that costs an insider their own money, which is why buying is the rarer and more meaningful signal. Selling is weaker evidence in either direction: insiders sell to diversify, to pay tax, or because a post-IPO lockup expired, and none of that is a view on the price. Where shares are held through a fund, the fund and its affiliated director each file the same sale, so we count matching filings once. This is disclosure history, not a prediction, and not advice.
Disclaimer. Nickelpie and its principals may buy, hold, or sell PFE or any security discussed at any time, and may have a position now. No one compensates us for covering PFE. This analysis is drawn from public information and is educational only. Ratings are impersonal opinions as of the publication date, not personalized advice, and we are not obliged to update them. Do your own research and consider your own situation and risk tolerance. See our disclosures.
Common questions
Is Pfizer (PFE) a good stock for the wheel strategy?
It fits a defensive, income-oriented wheel: ~$25 means 100 shares cost about $2,500, options are liquid, and it trades in a tight range with a large ~6.9% dividend. The caution is whythe yield is so high, patent cliffs and post-COVID revenue normalization. A fat yield, like a fat option premium, is often a warning, not a gift.
What put strike could a wheel seller consider on Pfizer?
With PFE near $24.54 and a 52-week low of $23.11, the range is tight and round numbers offer little discount. The panel on this page reads the strike off the live chain at roughly 0.25 delta, with the premium at the bid. Verify it on your own chain before acting.
Is Pfizer’s ~6.9% dividend safe?
No dividend is guaranteed, and a yield that high usually signals market doubt. Pfizer generates real cash, but patent cliffs and the fall in pandemic-era revenue pressure the earnings that fund it. Treat the dividend as a bonus if assigned, not a reason to oversize the position.
More wheel research
- Ford Motor Company (F)At ~$14 with a $10.68-$17.78 range, Ford is one of the most affordable liquid wheel candidates, ~$1,400 per contract.
- AT&T (T)A ~5.2% dividend and a steady $19.89-$29.79 range make AT&T a classic income-oriented wheel name at ~$2,200 per contract.
- eBay (EBAY)A cash-generative, lower-volatility marketplace near its highs, a quality wheel name, but ~$11,000 per contract puts it out of small-account range.
- GameStop (GME)Huge cash pile, elevated implied volatility, and a ~$2,200 contract, GME pays fat premium, and that premium is a warning as much as an opportunity.
- Amprius Technologies (AMPX)Silicon-anode battery maker near $10 with Q1 revenue up 2.5x to $28.5M and 2026 guidance of $130M+ and positive adjusted EBITDA, real growth, but volatile.
- Archer Aviation (ACHR)Pre-revenue eVTOL near $4.77 after a 19.6% jump on 4x volume on the Anduril autonomous-aircraft news. The one name here where the signal says sell calls, not puts.
- Infleqtion (INFQ)Newly public quantum pure-play near $8.97, 54% off its high. Revenue actually compounding ($10.9M to $28.8M to $33.6M) and three DOE Genesis Mission awards in July.
- Valens Semiconductor (VLN)A $187M chipmaker near $1.63 holding $78M of net cash, so 42% of the share price is cash. Real revenue of $70.7M at 62% gross margin, but still lossmaking.
- Quantum eMotion (QNC)A quantum-cybersecurity story near $2.09 with $37M of cash and a real NIST certification in progress, but only $21,753 of trailing revenue and an option chain that barely trades.
- Sidus Space (SIDU)A ~$180M space micro-cap near $2. After roughly $170M of raises, cash is close to $1.78 a share against a $1.85 price, but revenue has fallen four years running.
Before trading options, read the OCC's Characteristics and Risks of Standardized Options. Past performance does not predict future results.